Quercetin administration ameliorates pulmonary complications of cirrhosis in rats

Journal of Nutrition

Volumn 139, Issue 7, 2009, Pages 1339-1346

  Tieppo, Juliana ^a   Cuevas, María J ^c   Vercelino, Rafael ^a   Tuñón, María J ^c   Marroni, Norma P ^a,b   González Gallego, Javier ^c  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

^c UNIVERSITY OF LEÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; ENDOTHELIN B RECEPTOR; HEME OXYGENASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; QUERCETIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; ALANINE AMINOTRANSFERASE; ANTIOXIDANT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; HEPATOPULMONARY SYNDROME; HISTOPATHOLOGY; LIVER CIRRHOSIS; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; BLOOD; BLOOD PRESSURE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; LUNG; LUNG DISEASE; ORGAN SIZE; PATHOLOGY; RAT; WISTAR RAT;

RATTUS;

ALANINE TRANSAMINASE; ANIMALS; ANTIOXIDANTS; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; BLOOD PRESSURE; LIVER CIRRHOSIS; LUNG; LUNG DISEASES; MALE; ORGAN SIZE; QUERCETIN; RATS; RATS, WISTAR;

EID: 67649977035     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.3945/jn.109.105353     Document Type: Article

References (39)

1. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371:838-51.
2. Rodriguez-Roisin R, Krowka MJ, Herve P, Fallon MB, ERS Task Force Pulmonary-Hepatic Vascular Disorders (PHD) Scientific Committee. Pulmonary-hepatic vascular disorders (PHD). Eur Respir J. 2004;24:861-80.
3. Schenk P, Schoniger-Hekele M, Fuhrmann V, Madl C, Silberhumer G, Muller C. Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterology. 2003;125:1042-52.
4. Palma DT, Fallon MB. The hepatopulmonary syndrome. J Hepatol. 2006;45:617-25.
5. Ling Y, Zhang J, Luo B, Song D, Liu L, Tang L, Stockard CR, Grizzle WE, Ku DD, et al. The role of endothelin-1 and the endothelin B receptor in the pathogenesis of experimental hepatopulmonary syndrome. Hepatology. 2004;39:1593-602.
6. Rabiller A, Nunes H, Lebrec D, Tazi KA, Wartski M, Dulmet E, Libert JM, Mougeot C, Moreau R, et al. Prevention of gram-negative translocation reduces the severity of hepatopulmonary syndrome. Am J Respir Crit Care Med. 2002;166:514-7.
7. Zhang J, Ling Y, Tang L, Luo B, Chacko BK, Patel RP, Fallon MB. Pentoxifylline attenuation of experimental hepatopulmonary syndrome. J Appl Physiol. 2007;102:949-55.
8. Gallois C, Habib A, Tao J, Moulin S, Maclouf J, Mallat A, Lotersztain S. Role of NF-kappaB in the antiproliferative effect of endothelin-1 and tumor necrosis factor-alpha in human hepatic stellate cells. Involvement of cyclooxygenase-2. J Biol Chem. 1998;273:23183-90.
9. Majano P, Lara-Pezzi E, Ló pez-Cabrera M, Apolinario A, Moreno-Otero R, García-Monzón C. Hepatitis B virus X protein transactivates inducible oxide nitric synthase gene promoter through the proximal nuclear factor κb-binding site: evidence that cytoplasmatic localization of X protein is essential for gene transactivation. Hepatology. 2001;34:1218-24.
10. Lavrovsky Y, Song CS, Chatterjee B, Roy AK. Age-dependent increase of heme oxygenase-1 gene expression in the liver mediated by NFkappaB. Mech Ageing Dev. 2000;114:49-60.
11. Zhang J, Ling Y, Luo B, Tang L, Ryter SW, Stockard CR, Grizzle WE, Fallon MB. Analysis of pulmonary heme oxygenase-1 and nitric oxide synthase alterations in experimental hepatopulmonary syndrome. Gastroenterology. 2003;125:1441-51.
12. Vercelino R, Tieppo J, Dias AS, Marroni CA, Garcia E, Meurer L, Marroni NP. N-acetylcysteine effects on genotoxic and oxidative stress parameters in cirrhotic rats with hepatopulmonary syndrome. Basic Clin Pharmacol Toxicol. 2008;102:370-6.
13. Peres W, Tuñón MJ, Collado PS, Herrmann S, Marroni N, Gonzá lez-Gallego J. The flavonoid quercetin ameliorates liver damage in rats with biliary obstruction. J Hepatol. 2000;33:742-50.
14. Gaines DI, Fallon MB. Hepatopulmonary syndrome. Liver Int. 2004;24:397-401.
15. Skibola CF, Smith MT. Potential health impacts of excessive flavonoid intake. Free Radic Biol Med. 2000;29:375-83.
16. Boots AW, Haenen GR, Bast A. Health effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol. 2008;585:325-37.
17. Moreira AJ, Fraga C, Alonso M, Collado PS, Zetller C, Marroni C, Marroni N, González-Gallego J. Quercetin prevents oxidative stress and NF-kappaB activation in gastric mucosa of portal hypertensive rats. Biochem Pharmacol. 2004;68:1939-46.
18. Dias AS, Porawski M, Alonso M, Marroni N, Collado PS, Gonzá lez-Gallego J. Quercetin decreases oxidative stress, NF-kappaB activation, and iNOS overexpression in liver of streptozotocin-induced diabetic rats. J Nutr. 2005;135:2299-304.
19. Tieppo J, Vercelino R, Dias AS, Silva Vaz MF, Silveira TR, Marroni CA, Marroni NP, Henriques JA, Picada JN. Evaluation of the protective effects of quercetin in the hepatopulmonary syndrome. Food Chem Toxicol. 2007;45:1140-6.
20. Fallon MB, Abrams GA, McGrath JW, Hou Z, Luo B. Common bile duct ligation in the rat: a model of intrapulmonary vasodilatation and hepatopulmonary syndrome. Am J Physiol. 1997;272:G779-84.
21. Buege JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol. 1978;52:302-10.
22. Misra HP, Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem. 1972;247:3170-5.
23. Granger DL, Anstey NM, Miller WC, Weinberg JB. Measuring nitric oxide production in human clinical studies. Methods Enzymol. 1999;301:49-61.
24. García-Mediavilla V, Crespo I, Collado PS, Esteller A, Sánchez-Campos S, Tuñón MJ, González-Gallego J. The anti-inflammatory flavones quercetin and kaempferol cause inhibition of inducible nitric oxide synthase, cyclooxygenase-2 and reactive C-protein, and downregulation of the nuclear factor kappaB pathway in Chang liver cells. Eur J Pharmacol. 2007;557:221-9.
25. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)). Method. 2001;25:402-8.
26. Martínez-Fló rez S, Gutiérrez-Fernández B, Sánchez-Campos S, González-Gallego J, Tuñón MJ. Quercetin attenuates nuclear factor-kappaB activation and nitric oxide production in interleukin-1beta-activated rat hepatocytes. J Nutr. 2005;135:1359-65.
27. Tuñón MJ, Sánchez-Campos S, Gutiérrez B, Culebras JM, Gonzá lez-Gallego J. Effects of FK506 and rapamycin on generation of reactive oxygen species, nitric oxide production and nuclear factor kappa B activation in rat hepatocytes. Biochem Pharmacol. 2003;66:439-45.
28. Rodríguez-Roisin R, Krowka MJ. Hepatopulmonary syndrome: a liverinduced lung vascular disorder. N Engl J Med. 2008;358:2378-87.
29. Nunes H, Lebrec D, Mazmanian M, Capron F, Heller J, Tazi KA, Zerbib E, Dulmet E, Moreau R, et al. Role of nitric oxide in hepatopulmonary syndrome in cirrhotic rats. Am J Respir Crit Care Med. 2001;164:879-85.
30. Rolla G, Brussino L, Colagrande P, Dutto L, Polizzi S, Scappaticci E, Bergerone S, Morello M, Marzano A, et al. Exhaled nitric oxide and oxygenation abnormalities in hepatic cirrhosis. Hepatology. 1997;26:842-7.
31. Zhang M, Luo B, Chen SJ, Abrams GA, Fallon MB. Endothelin-1 stimulation of endothelial nitric oxide synthase in the pathogenesis of hepatopulmonary syndrome. Am J Physiol. 1999;277:G944-52.
32. Tang L, Luo B, Patel RP, Ling Y, Zhang J, Fallon MB. Modulation of pulmonary endothelial endothelin B receptor expression and signaling: implications for experimental hepatopulmonary syndrome. Am J Physiol Lung Cell Mol Physiol. 2007;292:L1467-72.
33. Sztrymf B, Rabiller A, Nunes H, Savale L, Lebrec D, Le Pape A, de Montrville V, Mazmanian M, Humbert M, et al. Prevention of hepatopulmonary syndrome and hyperdynamic state by pentoxifylline in cirrhotic rats. Eur Respir J. 2004;23:752-8.
34. Sogni P, Smith AP, Gadano A, Lebrec D, Higenbottam TW. Induction of nitric oxide synthase II does not account for excess vascular nitric oxide production in experimental cirrhosis. J Hepatol. 1997;26:1120-7.
35. Chabot F, Mestiri H, Sabry S, Dall'Ava-Santucci J, Lockhart A, Dinh-Xuan AT. Role of NO in the pulmonary artery hyporeactivity to phenylephrine in experimental biliary cirrhosis. Eur Respir J. 1996;9:560-4.
36. Lin HC, Cheng TH, Chen YC, Juan SH. Mechamisms of heme oxygenase-1 gene induction by quercetin in rat aortic smooth muscle cells. Pharmacology. 2004;71:107-12.
37. Chen YC, Ginès P, Yang J, Summer SN, Falk S, Russell NS, Schrier RW. Increased vascular heme oxygenase-1 expression contributes to arterial vasodilation in experimental cirrhosis in rats. Hepatology. 2004;39:1075-87.
38. Carter EP, Hartsfield CL, Miyazono M, Jakkula M, Morris KG Jr, McMurtry IF. Regulation of heme oxygenase-1 by nitric oxide during hepatopulmonary syndrome. Am J Physiol Lung Cell Mol Physiol. 2002;283:L346-53.
39. Friedman SL. The cellular basis of hepatic fibrosis. N Engl J Med. 1993;328:1828-35.